Post by Jubilant Therapeutics Inc

🚀 Exciting Leadership Update at Jubilant Therapeutics! 🚀 We are thrilled to announce the appointment of Daniel J. O'Connor as our new Chief Executive Officer. Dan brings over 25 years of leadership experience in biotechnology and oncology, with a proven track record of building and scaling innovative biopharmaceutical companies. His expertise in strategic partnerships and clinical development will be instrumental as we advance our mission to deliver transformative therapies for patients with difficult-to-treat cancers and autoimmune diseases. Welcome aboard, Dan! We look forward to an exciting journey ahead. Learn more about Jubilant Therapeutics and our pipeline: http://www.jubilanttx.com Press Release: https://lnkd.in/gfwxN_dE #Leadership #Biotech #Oncology #Innovation #JubilantTherapeutics #Epigenetics #CoREST #PRMT5 #PAD4 #autoimmune #nsclc #thrombocythemia #mpn #rheumatoidarthritis #glioma